Advertisement

DNP - Der Neurologe und Psychiater

, Volume 13, Issue 1, pp 40–51 | Cite as

Was hilft, wenn Sorgen außer Kontrolle geraten?

Generalisierte Angststörungen Teil II — Therapie
  • Hans-Peter VolzEmail author
  • Rolf-Dieter Stieglitz
Zertifizierte Fortbildung

Abstract

In der Planung einer individuell angepassten Therapie einer generalisierten Angststörung ist ein mehrdimensionales Vorgehen erforderlich, bei dem Primärsymptomatik, Komorbidität und die Verfügbarkeit therapeutischer Interventionen abgeklärt werden müssen. Eine vorwiegend psychopharmakologisch ausgerichtete Therapie kann im Einzelfall gerechtfertigt sein, wenn hierbei psychoedukative und verhaltenstherapeutische Aspekte nicht ausgeklammert werden.

Literatur

  1. 1.
    Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179: 15–22Google Scholar
  2. 2.
    Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP, World Council of Anxiety. WCA-recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectrums 2003; 8: 53–61Google Scholar
  3. 3.
    Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, Kutcher SP, Clary CM. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004; 161: 1642–1649Google Scholar
  4. 4.
    Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006; 9: 495–505Google Scholar
  5. 5.
    Ansseau M, Olie JP, von Frenckell R, Jourdain G, Stehle B, Guillet P. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder. Psychopharmacology 1991; 104: 439–443Google Scholar
  6. 6.
    Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 2006; 189: 264–272Google Scholar
  7. 7.
    Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005; 66: 94–99Google Scholar
  8. 8.
    Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 2002; 3: 171–199Google Scholar
  9. 9.
    Bandelow B, Rüther E. Treatment-resistant panic disorder. CNS Spectr 2004; 9: 725–739Google Scholar
  10. 10.
    Bandelow B. Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr 2006; 11: 21–28Google Scholar
  11. 11.
    Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 2006; 67: 1428–1434Google Scholar
  12. 12.
    Bandelow B, Boerner RJ, Kasper S, Linden M, Volz HP, Wittchen HU, Möller HJ. Die medikamentöse Behandlung der generalisierten Angststörung. Ein Konsensuspapier. PPT 2007; 14: 136–142Google Scholar
  13. 13.
    Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ, WFSBP Task Force on the treatment guidelines for anxiety, obsessive-compulsive, posttraumatic stress disorders. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders. First revision. World J Biol Psychiatry 2008; 9: 248–312Google Scholar
  14. 14.
    Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010; 13: 305–20Google Scholar
  15. 15.
    Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 2007; 40: 163–8Google Scholar
  16. 16.
    Becker ES, Margraf J. Generalisierte Angststörung. Ein Therapieprogramm. Weinheim: Beltz PVU, 2002Google Scholar
  17. 17.
    Becker ES, Hoyer J. Generalisierte Angststörung. Göttingen: Hogrefe, 2005Google Scholar
  18. 18.
    Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17: 65–69Google Scholar
  19. 19.
    Bjerrum H, Allerup P, Thunedborg K, Jakobsen K, Bech P. Treatment of generalized anxiety disorder: comparison of a new beta-blocking drug (CGP 361 A), low-dose neuroleptic (flupenthixol), and placebo. Pharmacopsychiatry 1992; 25: 229–232.Google Scholar
  20. 20.
    Boyer WF, Feighner JP. A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. Int Clin Psychopharmacol 1993; 8: 173–176Google Scholar
  21. 21.
    Bradwejn J. Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions. Can J Psychiatry 1993; 38 (Suppl 4): S109–S113Google Scholar
  22. 22.
    Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005; 66: 1321–1325Google Scholar
  23. 23.
    Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels. Sertraline treatment for generalized anxiety disorder: A randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 874–881Google Scholar
  24. 24.
    Bryans JS, Wustrow DJ (1999). 3-Substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999; 16: 519–526Google Scholar
  25. 25.
    Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl 2003; 417: 38–50.Google Scholar
  26. 26.
    Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999; 60: 528–535.Google Scholar
  27. 27.
    Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004; 19: 234–240Google Scholar
  28. 28.
    Dooley DJ, Mieske CA, Borosky SA. Inhibition of K+-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000a; 280: 107–110CrossRefGoogle Scholar
  29. 29.
    Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependant modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000b: 1086–1093Google Scholar
  30. 30.
    Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 1984; 4: 125–129Google Scholar
  31. 31.
    Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1991; 105: 428–432Google Scholar
  32. 32.
    Eriksson H, Mezhebovsky I, Mägi K, Chouinard G, She F, Datto C. Once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalized anxiety disorder (GAD): results from a double-blind, randomized, placebo-controlled study. Poster presented at 47th American College of Neuropsychopharmacology Annual Meeting, Scottdale, Arizona, USA, 7.-11. Dezember, 2008Google Scholar
  33. 33.
    Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982; 43: 103–108Google Scholar
  34. 34.
    Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240–249Google Scholar
  35. 35.
    Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23: 18–28Google Scholar
  36. 36.
    Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001; 132: 1–4PubMedPubMedCentralGoogle Scholar
  37. 37.
    Fink K, Dooley DJ, Meder WP, Suman-Chauhan N, Duffy S, Clusmann H, Gothert M. Inhibition of neuronal Ca2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 2002; 42: 229–236Google Scholar
  38. 38.
    Fontaine R, Annable L, Chouinard G, Ogilvie RI. Bromazepam and diazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. J Clin Psychopharmacol 1983; 3: 80–87Google Scholar
  39. 39.
    Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2-delta subunit of a calcium channel. J Biol Chem 1996; 271: 5768–5776PubMedPubMedCentralGoogle Scholar
  40. 40.
    Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 2000; 283: 3082–3088Google Scholar
  41. 41.
    Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58: 681–686Google Scholar
  42. 42.
    Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005; 87: 161–167Google Scholar
  43. 43.
    Gross C, Hen R. Genetic and environmental factors interact to influence anxiety. Neurotox Res 2004; 6: 493–501Google Scholar
  44. 44.
    Hildalgo RB, Tupler LA, Davidson JRT (2007) An effect-size analysis of pharmacological treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21: 864–872Google Scholar
  45. 45.
    Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988; 49: 293–301Google Scholar
  46. 46.
    Hunot V, Churchill R, Silva de Lima M, Teixeira V. Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001848.Google Scholar
  47. 47.
    Jacobson AF, Dominguez RA, Goldstein BJ, Steinbook RM. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 1985; 5: 290–296Google Scholar
  48. 48.
    Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24: 87–96Google Scholar
  49. 49.
    Khan A, Joyce M, Atkinson S, Eggens I, Baldytcheva I, Eriksson H. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder.v J Clin Psychopharmacol. 2011; 31: 418–28Google Scholar
  50. 50.
    Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011; 26: 11–24.Google Scholar
  51. 51.
    Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19Google Scholar
  52. 52.
    Kragh-Sørensen P, Holm P, Fynboe C, Schaumburg E, Andersen B, Bech P, Pichard J. Bromazepam in generalized anxiety. Randomized, multi-practice comparisons with both chlorprothixene and placebo. Psychopharmacology 1990; 100: 383–386Google Scholar
  53. 53.
    Laux G. Pharmakopsychiatrie. Stuttgart: Fischer, 1992Google Scholar
  54. 54.
    Lieb R. Generalisierte Angststörung. In {ebRD Stieglitz, U Baumann, M Perrez} (Hrsg), Fallbuch zur Klinischen Psychologie und Psychotherapie. Bern: Huber, 2007, S. 181–191Google Scholar
  55. 55.
    Livingston MG. Benzodiazepine dependence. Br J Hosp Med 1994; 51: 281–286Google Scholar
  56. 56.
    Lydiard RB, Ballenger JC, Rickels K. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry 1997; 58: 11–18Google Scholar
  57. 57.
    Maneuf YP, McKnight AT. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001; 134: 237–240PubMedPubMedCentralGoogle Scholar
  58. 58.
    Meredith C, Cutler A, Neijber A, She F, Eriksson H (2008) Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the treatment of generalized anxiety disorder (GAD). Poster presented at 21st Congress of the European College of Neuropsychopharmacology, Barcelona, Spanien, 30. August–3. September, 2008Google Scholar
  59. 59.
    Möller HJ, Volz HP, Reimann IW, Stoll KD. Opipramol for the treatment of generalized anxiety disorder: a placebo- controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001; 21: 59–65Google Scholar
  60. 60.
    Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006; 67: 771–782Google Scholar
  61. 61.
    Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. Can J Clin Pharmacol 1999; 6: 69–83Google Scholar
  62. 62.
    Newman MG, Zuellig AR, Kachin KE, Constantino MJ, Cashman-McGrath L. Preliminary reliability and validity of the Generalized Disorder Questionnaire-IV — A revised self-report diagnostic measure of generalized anxiety disorder. Behav The 2002; 33: 215–233.Google Scholar
  63. 63.
    Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol 2004; 19: 331–336Google Scholar
  64. 64.
    Nutt DJ. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectr. 2005; 10: 49–56.Google Scholar
  65. 65.
    Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993; 150: 1485–1490Google Scholar
  66. 66.
    Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JRT, Liu-Dumaw M. Pregabalin in generalized anxiety disorder. A placebo-controlled trial. Am J Psychiatry 2003; 60: 533–540Google Scholar
  67. 67.
    Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder. Double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151–158Google Scholar
  68. 68.
    Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Lyengar MK. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 350–357Google Scholar
  69. 69.
    Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study. Biological Psychiatry 2006; 59: 211–215Google Scholar
  70. 70.
    Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42: 757–763PubMedPubMedCentralGoogle Scholar
  71. 71.
    Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, Danton J. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43: 81–86Google Scholar
  72. 72.
    Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation [published erratum appears in Arch Gen Psychiatry 1991; 48: 51]. Arch Gen Psychiatry 1990; 47: 899–907Google Scholar
  73. 73.
    Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50: 884–895Google Scholar
  74. 74.
    Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 1997; 17: 272–277Google Scholar
  75. 75.
    Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000a; 157: 968–974.CrossRefGoogle Scholar
  76. 76.
    Rickels K, DeMartinis N, Aufdembrinke B. A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J Clin Psychopharmacol 2000b; 20: 12–18.CrossRefGoogle Scholar
  77. 77.
    Rickels K, Rynn MA. What is generalized anxiety disorder? J Clin Psychiatry 2001; 62 (suppl 11): 4–12Google Scholar
  78. 78.
    Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 749–756Google Scholar
  79. 79.
    Ross CA, Matas M. A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder. Can J Psychiatry 1987; 32: 351–355Google Scholar
  80. 80.
    Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158: 2008–2014Google Scholar
  81. 81.
    Schneider S, Margraf J. Diagnostisches Interview bei psychischen Störungen (DIPS). (3. Aufl.). Berlin: Springer, 2006Google Scholar
  82. 82.
    Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 1990; 47: 908–915Google Scholar
  83. 83.
    Schweizer E, Rickels K, De Martinis N, Case G, Garcia-Espana F. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. Psychol Med 1998; 28: 713–720Google Scholar
  84. 84.
    Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. New Engl J Med 1993; 13: 1398–1405Google Scholar
  85. 85.
    Smith DE, Landry MJ. Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxification setting and benzodiazepine-polydrug abuse. J Psychiatr Res 1990; 24 (Suppl 2): 145–156Google Scholar
  86. 86.
    Spitzer R, Kroehnke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder; The GAD-7. Arch Intern Med 2006; 166.1092–1097Google Scholar
  87. 87.
    Stahl MM, Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Taylor NF, Fletcher AP, Schou JS. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163–169Google Scholar
  88. 88.
    Stieglitz RD. Diagnostik und Klassifikation in der Psychiatrie. Stuttgart: Kohlhammer, 2008Google Scholar
  89. 89.
    Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK, Paroxetine Generalized Anxiety Disorder Study Team. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003; 64: 250–258Google Scholar
  90. 90.
    Turowsky J, Barlow DH. Generalisiertes Angstsyndrom. In Margraf J (Hrsg.) Lehrbuch der Verhaltenstherapie. Band 2: Störungen Glossar (2. Aufl.). Berlin: Springer, 2000, S. 87–106Google Scholar
  91. 91.
    Vauth R, Stieglitz RD. Kognitiv-verhaltenstherapeutische Ansätze in der Gruppenpsychotherapie. In: Freyberger HJ, Schneider W, Stieglitz RD (Hrsg.) Kompendium Psychiatrie, Psychotherapie, Psychosomatische Medizin (1. Auflage). Bern: Huber, S. 511–529Google Scholar
  92. 92.
    Volz HP. Medikamente für GAD. Bandelow B (Hrsg) Taschenatlas GAD, Linkenheim-Hochstetten: Aesopus, 2006, S. 70–89Google Scholar
  93. 93.
    Volz HP. Das dual wirksame Duloxetin in der Behandlung der Generalisierten Angststörung. Die Psychiatrie 2008; 3: 217–224Google Scholar
  94. 94.
    Volz HP (2009) Therapieresistenz in der Behandlung von Angststörungen. In: Schmauss M, Messer T (Hrsg). Therapieresistenz bei psychischen Erkrankungen. München: Urban & Fischer. S. 101–108, 2009Google Scholar
  95. 95.
    Volz HP, Stieglitz RD. Generalisierte Angststörung. Stuttgart: Schattauer, 2010Google Scholar
  96. 96.
    Volz HP, Gastpar M, Kasper S, Möller HJ, Müller WE. Subsyndromale Angststörungen: Definition, Messparameter und Epidemiologie. J Neruol Neurochir Psychiatr 2011; 12: 162–167Google Scholar
  97. 97.
    Wells A. Cognitive therapy of anxiety disorders. Chichester: Wiley, 1997Google Scholar
  98. 98.
    Wittchen HU, Pfister H (Hrsg) Instruktionsmanual zur Durchführung von DIA-X-Interviews. Fankfurt: Swets Services, 1997Google Scholar
  99. 99.
    White J, Keeman M, Brooks N. Stress control: a controlled comparative investigation of large group therapy for generalized anxiety disorder. Behav Psychother 1992; 20: 97–114Google Scholar
  100. 100.
    White J. Treating anxiety and stress. A group psycho-educational approach using brief CBT. Chichester, Wiley, 2000Google Scholar
  101. 101.
    Zubrägel D, Linden M. Generalisierte Angststörung. In: Linden M, Hautzinger M (Hrsg). Psychotherapiemanual. Berlin: Springer. S. 511–516, 2008Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2012

Authors and Affiliations

  1. 1.Krankenhaus für Psychiatrie, Psychotherapie und Psychosomatische Medizin Schloss WerneckWerneckDeutschland
  2. 2.Universitäre Psychiatrische Kliniken (UPK) BaselBaselDeutschland

Personalised recommendations